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INTRODUCTION 
 Ecdysteroids represent a large and diverse family of steroid hormones in nature, with 
representatives in both insects and plants. They regulate molting and reproduction in 
arthropods, and play defensive role against herbivores in plants. The most abundant 
ecdysteroid in nature is 20-hydroxyecdysone (20E, 1), which is also recognized as the major 
biologically active ecdysteroid, and usually it is accompanied by a large number of minor 
phytoecdysteroids with lower quantity in plants. More than 480 ecdysteroids have been 
isolated from plant sources in the past five decades, and ca. one quarter of them have 
been discovered by the research group of Prof. Báthori at the University of Szeged. 
 Their structure can be characterized with a steroid skeleton, in which the A/B ring 
junction is normally cis, while the C/D ring junction is almost always trans. A 7-en-6-one 
chromophore group can be found in ring B, and a side-chain is usually attached to C-17. 
Several hydroxyl groups make these compounds rather polar, and occasionally form 
glycosidic, ester or ether bonds. 
 Due to their ability to disrupt hormonal processes in arthropods, ecdysteroids have 
been investigated to develop safe natural insecticides, however they failed to reach the 
market for this use. These compounds show extremely low toxicity in mammals, and do 
not appear to interact with the vertebrate steroid hormone system, still they have been 
found to exert numerous beneficial effects. Anabolic activity is such an example, and has 
been investigated in numerous studies, presuming Akt activation as the background of the 
observed increased protein synthesis. It is suggested that metabolites of 20E (such as 
poststerone) might be responsible for this activity. Because of the “general strengthening” 
activity of 20E, it has been marketed all around the world in the form of dietary 
supplementary products. Wound-healing, antidiabetic, hypocholesterolaemic activities 
have also been attributed to this compound. 
 20E is also a good candidate for semi-synthetic transformations, and in a number of 
studies it has been subjected to chemical modifications to obtain other, less accessible 
ecdysteroids in larger quantities.  Previously, our research group has put a large number of 
natural ecdysteroids and some of their semi-synthetic derivatives under investigation to 
observe their effect on multi-drug resistance (MDR) in cancer. Based on these 
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observations, relevant structure-activity relationships (SARs) have been established, which 
served as a starting point for the hereby presented Ph.D. study. 
 
OBJECTIVES 
 In search for novel ecdysteroid derivatives as potential modulators of MDR, the 
following goals were set up: 
 1. Preparation of new semi-synthetic ecdysteroid derivatives with potent biological 
activity. The proposed structural modifications include the formation of dioxolanes, base-
catalyzed autoxidation, side-chain cleavage and fluorination. 
 2. Biological evaluation of the obtained ecdysteroids. Testing compounds in vitro for 
their 1) anti-proliferative activity on various sensitive and MDR cancer cell lines; 2) 
functional ABCB1 efflux pump inhibition; 3) chemo-sensitizing activity in combination with 
doxorubicin or other chemotherapeutics; and/or 4) effect on Akt-phosphorylation. 
 3. Establishing new structure-activity relationships (SARs). Observing how structural 
modifications on the tested compounds affect their biological activity related to MDR. 
 
MATERIALS AND METHODS 
Starting materials 
 The starting material, 20E (1, 90% originated from the roots of Cyanotis arachnoidea) 
was purchased from Shaanxi KingSci Biotechnology Co. Ltd. (Shanghai, China), and further 
purified by crystallization. Dacryhainansterone (2), 2-deoxy-20-hydroxyecdysone (3), 
ajugasterone C (4) and polypodine B (5) were previously isolated from Ajuga, Serratula and 
Silene species. 
 
Preparation of ecdysteroid derivatives 
 Ecdysteroid dioxolanes (6-28) were obtained from 20E in one step by applying various 
aldehydes/ketones under acidic conditions – provided by phosphomolybdic acid – in 
methanol. The reaction mixtures were purified by means of column chromatography (CC), 
rotational planar chromatography (RPC), reversed-phase high performance liquid 
chromatography (RP-HPLC), or recrystallization from acetonitrile. Compounds 29-36 were 
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obtained in a similar fashion, but in two consecutive steps, in which a 20,22-
monosubstituted ecdysteroid dioxolane was subjected to substitution at the 2,3-diol. 
Compounds 37-42 were obtained from 20E by first protecting the more reactive 20,22-diol 
with phenylboronic acid, which protecting group was later removed by applying H2O2 after 
dioxolane formation at the 2,3 position. Pure products were obtained by means of RPC. 
 Base-catalyzed autoxidation of 20E was performed by applying NaOH in aqueous 
methanol, yielding oxidized ecdysteroid derivatives (43-50) after multiple steps of 
purification with centrifugal partition chromatography (CPC), CC, preparative thin layer 
chromatography (prep. TLC) and RP-HPLC. This reaction was also monitored by HPLC in a 
longitudinal study, and concentrations of compounds were determined at various times. 
 Compounds 51-55 were obtained by oxidative side-chain cleavage by applying 
[bis(trifluoroacetoxy)iodo]benzene (PIFA) on corresponding ecdysteroids (1-5, 
respectively), and means of CPC, RPC and RP-HPLC were used for purification. Poststerone 
(51) was subjected to dioxolane formation involving the 2,3-diol, yielding compounds 56-
64. These reactions were performed by applying p-toluenesulfonic acid as catalyst, and 
reaction products were purified by RPC and RP-HPLC. 
 Compound 20 was subjected to fluorination with (diethylamino)sulfur trifluoride 
(DAST) yielding compounds 65-68, which were further purified by CC and RP-HPLC. 
 
Procedures for structure elucidation 
 The obtained compounds were characterized and their structures were elucidated by 
means of different spectroscopic methods (MS, 1D- and 2D-NMR). 
 
Biological evaluation of the compounds 
 In the experiments on bioactivity, ten human derived cell lines were used (breast 
cancer cells: MCF7, MCF7dox, MDA-MB-231, MDA-MB-361, T47D; prostate cancer cells: PC3 
and LNCaP; epidermal carcinoma cells: KB-3-1 and KB-C-1; and a neuroblastoma cell line: 
SH-SY5Y). Two mouse T-cell lymphoma cell lines were used: the L5178 cell line, and its 
multi-drug resistant L5178MDR counterpart. Akt-phosphorylation was tested on C2C12 
mouse skeletal myoblasts. 
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 Compounds were tested for their anti-proliferative activity by a serial-dilution method 
in 96-well flat-bottom microtiter plates, using the MTT assay. Inhibition of ABCB1 function 
was investigated on L5178MDR cells through the intracellular retention of rhodamine 123, a 
fluorescent dye, evaluated by flow cytometry. Combination assays were performed using 
the checkerboard microplate method, where cells were incubated with an anticancer agent 
(doxorubicin, paclitaxel, cisplatin or vincristine) and the tested compound. Where it was 
possible, combination indices (CI) were calculated by means of the median-effect equation, 
where CI < 1, CI = 1 and CI > 1 represent synergism, additive effect and antagonism, 
respectively. Oxidized ecdysteroid derivatives were tested for their effect on Akt-
phosphorylation on C2C12 mouse skeletal myoblasts. 
 
RESULTS AND DISCUSSION 
Preparation of semi-synthetic ecdysteroid derivatives 
 The diols of 20E (namely at C-2,3 and C-20,22) were targeted by acid catalyzed reaction 
with aldehydes or ketones, in which a dioxolane ring was formed at C-20,22 (compounds 6-
19), at C-2,3 (compounds 37-42) or at both positions (compounds 20-36). From the two 
diols, the one at C-20,22 appeared to be more reactive. At the newly created stereogenic 
centers, the larger substituent attached to C-29 preferentially took the R
4
-position, while at 
C-28, R
1
-position was preferred. Structures can be seen on Fig. 1. 
 The autoxidation of 20E by molecular oxygen was catalyzed by applying a base (NaOH) 
in relatively low concentration, and yielded compounds 43-50 (see Fig. 2.). The reaction 
was carried out and monitored, and the formation of each isolated product over various 
reaction times was studied. Compounds 47 and 48 represent a very rare case of 
desmotropism, a type of tautomerism where both forms may be isolated in a stable form 
without detectable coexistence of the other tautomer when dissolved in the same solvent.  
 Side-chain cleavage between the hydroxylated C-20 and C-22 carbon atoms of various 
ecdysteroids (1-5) was performed by applying PIFA, yielding compounds 51-55 (see Fig. 3.). 
 Dioxolane formation performed on the 2,3-diol of poststerone (51) was carried out in a 
similar way to the synthesis of dioxolane derivatives of 20E, however, longer reaction times 
and larger amounts of the reagent were applied to yield compounds 56-64 (see Fig. 4.) 
 Reaction of compound 20 with DAST resulted in fluorination or elimination of the 14-
OH and fluorination of the 25-OH group, yielding compounds 65-68 (see Fig. 5.).  
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24 -Ph -H -H -Ph 
25 -H -Ph -H -Ph 
26 -n-Pr -H -H -n-Pr 
27 -n-Bu -H -H -n-Bu 
28 -Et -Et -Et -Et 
29 -Me -H -Me -Me 
30 -Et -Me -Me -Me 
31 -Me -Me -H -n-Pr 
32 -Me -Me -Et -Et 
33 -Me -Me -Me -i-Bu 
34 -Me -Me -H -Ph 
35 -Me -Me -Me -Ph 
36 -n-Pr -H -Me -Me 
37 -Et -Et - - 
38 -Me -Me - - 
39 -Et -H - - 
40 n-Bu -H - - 
41 -Me -i-Bu - - 
42 -i-Bu -Me - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 R
1 
R
2
 R
3
 R
4
 
6 - - -Me -Me 
7 - - -H -n-Pr 
8 - - -H -n-Bu 
9 - - -Et -Et 
10 - - -Me -i-Bu 
11 - - -H -3-MeO-4-OH-Ph 
12 - - -3-MeO-4-OH-Ph -H 
13 - - -H -E-ethenylbenzyl 
14 - - -H -Z-ethenylbenzyl 
15 - - -H -4-benzyloxyphenyl 
16 - - -4-benzyloxyphenyl -H 
17 - - -Me -Ph 
18 - - -Me -Et 
19 - - -H -Ph 
20 -Me -Me -Me -Me 
21 -Me -Et -Me -Et 
22 -Et -Me -H -Me 
23 -Me -H -Me -Et 
     
     
     
     
 
Figure 1 – Structures of the semi-synthesized ecdysteroid dioxolane derivatives (6-42) 
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Figure 2 – Oxidized ecdysteroid derivatives (43-50) obtained from the autoxidation of 20E 
 
 
Figure 3 – Ecdysteroid derivatives (51-55) obtained by side-chain cleavage 
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Figure 4 – Ecdysteroid derivatives (56-64) synthesized from poststerone  
 
 
Figure 5 – Ecdysteroid derivatives (65-68) obtained from the DAST-mediated fluorination of 20 
 
Structure elucidation of the prepared ecdysteroids 
 Mass spectra of the compounds were recorded by APCI and ESI measurements in 
positive mode. Structure determination was performed by comprehensive 1D and 2D NMR 
techniques. In case of the dioxolane derivatives, a comparison of the 
1
H and 
13
C chemical 
shifts of 20E in positions 2, 3, 20 and 22 with the corresponding values of the dioxolane 
compounds showed pronounced deshielding, thereby proving that dioxolane formation 
took place. The configuration of the newly obtained stereogenic centers at C-28 and C-29 
was elucidated by 2D ROESY and sel-ROE experiments. Structural modifications in the 
steroid skeleton during the autoxidation of 20E manifested in the appearance of additional 
double bonds and hydroxyl groups, whose presence was reflected in the downfield shift of 
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corresponding signals in the 
1
H and 
13
C spectra. The unique α-configuration of H-5 in 
compound 44 was unequivocally established by sel-ROESY measurements. Side-chain 
cleavage led to the formation of a carbonyl group at C-20, with a characteristic signal (δC = 
212.5 ppm) appearing in the 
13
C NMR spectra. In case of poststerone dioxolanes, the 
presence of a dioxolane ring at C-2,3 was reflected by the pronounced deshielding 
observed in the chemical shifts of H-2,3 and C-2,3 in the corresponding spectra. Similarly to 
the case of other ecdysteroid dioxolanes, the larger substituent connected to the newly 
created stereogenic center preferred to take the R
1
-position, which was confirmed by 1D 
ROESY experiments. In case of fluorinated ecdysteroid derivatives, fluorine substitution 
manifested in characteristic changes in the NMR spectra. In the α-position, namely directly 
on the substituted carbon, a ca. 20-25 ppm paramagnetic shift and in the β-position a ca. 
2-3 ppm diamagnetic shift was observed, which effect decreased below 1 ppm in the γ-
position. In addition to these, both the 
1
H and the 
13
C spectra showed signal splitting 
caused by characteristic direct, geminal and vicinal couplings. Evidence was found that no 
configurational change took place at C-14 during fluorine substitution, thus supporting the 
expected SN1 reaction mechanism.  
 
Biological activity and related SAR of the obtained compounds 
 The ecdysteroid dioxolanes (6-42 and 56-64) were tested for their anti-proliferative 
activity on various cell lines. The majority of the tested compounds – in contrast with the 
parental 20E – showed anti-proliferative activity in the bioassays. However, in most cases, 
this activity proved to be weak on the L5178 cell line, and often somewhat even less 
pronounced on its resistant counterpart, L5178MDR. It was observed, that from the two 
possible substitutions of 20E leading to dioxolane formation, the one taking place at C-
20,22 has greater effect on anti-proliferative activity, while the impact of 2,3-substitution is 
negligible. For example, the 2,3-monosubstituted derivatives of 20E (compounds 37-42) – 
with an intact side chain – showed no anti-proliferative activity on either cell lines, just like 
20E. However, dioxolane formation at C-20,22 might lead to marked increase in cell growth 
inhibition, which becomes more pronounced when an apolar aromatic group is part of the 
substituent (as in case of compounds 13-16, 24, 25, 34  and 35). Removal of the side-chain 
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compound 
IC50 (μM) 
L5178 L5178MDR 
1 (20E) > 150 > 150 
6 > 150 > 150 
7 40.6 ± 3.6 > 150 
8 21.4 ± 1.4 57.8 ± 5.7 
9 77.0 ± 1.5 92.7 ± 2.0 
10 18.5 ± 1.8 35.7 ± 0.5 
11 92.3 ± 23.1 > 150 
12 98.9 > 150 
13 36.7 ± 0.8 89.4 ± 14.4 
14 45.0 ± 9.6 > 150 
15 31.6 ± 5.3 43.2 ± 2.7 
16 41.0 ± 6.8 59.5 ± 5.8 
17 34.1 ± 3.3 38.8 ± 0.4 
18 68.9 ± 2.1 > 150 
19 50.0 ± 3.4 > 150 
20 82.9 ± 1.0 106.1 ±3.3 
21 51.2 ± 1.5 56.0 ± 6.4 
22 99.6 ± 5.2 > 150 
23 52.6 ± 1.5 87.8 ± 10.9 
24 20.3 ± 0.8 22.4 ± 0.8 
25 30.2 ± 1.2 38.3 ± 1.1 
26 19.5 ± 2.6 30.6 ± 1.4 
 
 
compound 
IC50 (μM) 
L5178 L5178MDR 
27 19.9 ± 0.03 25.5 ± 3.4 
28 52.6 ± 12.9 49.7 ± 3.9 
29 > 150 > 150 
30 > 150 > 150 
31 75.2 ± 12.1 64.4 ± 13.7 
32 77.5 ± 20.7 75.9 ± 3.1 
33 72.2 ± 9.8 66.8 ± 4.7 
34 42.0 ± 18.9 42.7 ± 2.6 
35 41.6 ± 6.7 46.5 ± 7.0 
36 62.6 ± 16.8 64.7 ± 7.3 
56 95.7 ± 0.6 > 150 
57 91.1 ± 4.2 > 150 
58 74.3 ± 2.3 > 150 
59 97.8 ± 2.1 > 150 
60 72.2 ± 0.6 > 150 
61 59.6 ± 0.8 55.4 ± 4.9 
62 92.5 ± 1.0 85.7 ± 1.1 
63 95.2 ± 1.4 87.7 ± 1.1 
64 97.0 ± 5.8 91.6 ± 7.0 
65 48.3 ± 0.2 50.1 ± 2.1 
66 14.6 ± 0.3 19.3 ± 0.5 
67 14.1 ± 0.8 17.4 ± 1.2 
68 88.6 ± 1.1 82.3 ± 1.4 
 
 
compound 
IC50 (μM) 
MCF-7 T47D MDA-MB-231 MDA-MB-361 SH-SY5Y 
20 75.1 ± 3.4 84.7 ± 3.9 106.1 ± 7.2 69.2 ± 6.0 126.8 ± 9.8 
65 63.1 ± 2.3 70.3 ± 1.3 48.9 ± 2.0 30.9 ± 2.6 70.7 ± 4.1 
66 30.1 ± 0.8 10.9 ± 0.3 38.5 ± 3.8 13.8 ± 0.4 20.8 ± 0.3 
67 43.8 ± 1.7 17.4 ± 1.0 50.2 ± 2.6 11.8 ± 1.2 18.8 ± 1.2 
68 127.5 ± 4.3 49.2 ± 5.0 98.4 ± 17.2 53.8 ± 5.7 125.6 ± 13.2 
 
does not appear to contribute significantly to the anti-proliferative activity of the 
compounds. In case of compounds 20 and 65-68, fluorine substitution at C-25 or at C-14 
and C-25 had little effect on the very mild anti-proliferative activity of 20, however, 
presence of a ∆
14,15
 double bond markedly increased the activity. Results are shown on 
Table 1 and 2). 
 
Table 1 – IC50 values of ecdysteroid derivatives (6-36 and 56-68) tested on the parental L5178 and 
multi-drug resistant L5178MDR cell line, presented as the average of 3 independent experiments ± 
standard error of the mean (SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – IC50 values of the ecdysteroid derivatives 65-68 compared to that of the parental compound 
20, tested on breast cancer (MCF-7, MDA-MB-231, MDA-MB-361 and T47D) and neuroblastoma (SH-
SY5Y) cell lines. Values are presented as the average of 3 independent experiments ± SEM. 
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compound 
FAR 
2 μM 20 μM 
1 (20E) 1.70 1.76 
6 - 1.53 
7 1.02 4.04 
8 2.40 40.76 
9 1.42 1.40 
10 1.53 98.74 
11 0.87 7.85 
12 0.87 0.87 
13 0.77 1.01 
14 0.76 0.91 
15 1.11 * 
16 1.00 109.40 
17 1.21 94.56 
18 0.95 1.04 
19 1.04 1.69 
20 3.33 11.28 
21 29.96 45.35 
22 6.47 53.49 
23 10.00 55.81 
24 51.97 * 
25 1.08 82.68 
26 43.81 * 
   
   
   
   
   
   
   
   
   
 
compound 
FAR 
2 μM 20 μM 
27 114.64 * 
28 14.71 * 
29 3.88 14.07 
30 1.41 17.67 
31 1.68 60.67 
32 2.21 68.46 
33 51.67 75.17 
34 10.98 67.78 
35 61.67 * 
36 3.47 63.22 
56 1.06 1.54 
57 1.20 1.25 
58 1.02 4.24 
59 0.84 1.02 
60 0.95 2.95 
61 2.63 30.85 
62 0.84 1.16 
63 0.73 0.87 
64 0.75 1.10 
65 1.59 38.62 
66 1.28 57.36 
67 31.15 109.37 
68 11.02 89.78 
 
 
 The dioxolane derivatives (6-36 and 56-68) were also tested for their inhibiting activity 
on the ABCB1 efflux transporter. Usually, applying higher concentration (20 μM) of the 
compound led to more potent inhibition, and in some cases resulted in cytotoxicity. It 
seems that side-chain cleavage does not lead to the appearance of pump inhibition even if 
it is accompanied by dioxolane formation at C-2,3, as none of the poststerone derivatives 
(56-64, with the exception of 61) showed any activity in this bioassay, similarly to 20E. In 
case of compounds 65-68, elimination of 14-OH, as well as fluorination at C-14 or C-25, 
manifested in a significant increase in the ABCB1 inhibitory activity (see Table 3). 
 
Table 3 – Fluorescence activity ratio (FAR) values in presence of 2 and 20 μM of compounds (6-36 and 
56-68). Asterisk (*) represent that the compound showed cytotoxicity at this concentration and it was 
irrelevant to calculate the FAR value. FAR values of the positive control verapamil (20.4 μM) and the 
negative control DMSO (0.2%) were 5.73 and 0.72, respectively. 
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drug 
ratio 
CI values at 
CIavg r 
ED50 ED75 ED90 
23 20.4 : 1 0.31 0.22 0.17 0.21 0.978 
24 20.4 : 1 0.70 0.69 0.74 0.71 0.998 
25 20.4 : 1 0.54 0.40 0.31 0.38 0.947 
26 20.4 : 1 0.44 0.32 0.27 0.31 1.000 
27 20.4 : 1 0.39 0.38 0.39 0.39 0.979 
28 40.8 : 1 0.26 0.30 0.35 0.32 0.992 
29 20.4 : 1 0.31 0.18 0.15 0.19 0.962 
30 20.4 : 1 0.34 0.18 0.15 0.19 0.956 
31 20.4 : 1 0.21 0.12 0.07 0.11 0.956 
32 20.4 : 1 0.20 0.13 0.10 0.13 0.958 
33 20.4 : 1 0.23 0.08 0.06 0.09 0.984 
34 20.4 : 1 0.12 0.10 0.12 0.11 0.963 
35 20.4 : 1 0.18 0.12 0.12 0.13 0.999 
36 20.4 : 1 0.15 0.13 0.14 0.14 0.999 
65 20.4 : 1 0.19 0.19 0.19 0.19 0.908 
66 20.4 : 1 0.54 0.44 0.37 0.42 0.989 
67 20.4 : 1 0.48 0.36 0.28 0.34 0.983 
68 20.4 : 1 0.21 0.12 0.07 0.11 0.957 
 
 
 
drug 
ratio 
CI values at 
CIavg r 
ED50 ED75 ED90 
1 20.4 : 1 2.00 2.02 2.04 2.03 0.997 
6 20.4 : 1 0.84 0.54 0.35 0.49 0.955 
7 81.6 : 1 0.91 0.31 0.11 0.31 0.989 
8 40.8 : 1 0.56 0.58 0.78 0.68 0.870 
9 40.8 : 1 0.50 0.26 0.14 0.24 0.959 
10 81.6 : 1 0.70 0.44 0.28 0.40 0.936 
11 20.4 : 1 0.95 0.53 0.34 0.51 0.945 
12 40.8 : 1 0.86 0.48 0.27 0.44 0.958 
13 81.6 : 1 0.82 0.68 0.74 0.73 0.950 
14 40.8 : 1 0.92 0.81 0.94 0.89 0.991 
15 20.4 : 1 0.66 0.61 0.70 0.66 0.954 
16 20.4 : 1 0.20 0.25 0.33 0.28 0.946 
17 20.4 : 1 0.63 0.47 0.61 0.57 0.820 
18 20.4 : 1 0.92 0.59 0.41 0.55 0.968 
19 40.8 : 1 0.84 0.81 0.91 0.87 0.967 
20 40.8 : 1 0.26 0.14 0.08 0.13 0.996 
21 20.4 : 1 0.31 0.25 0.24 0.25 0.999 
22 20.4 : 1 0.23 0.16 0.15 0.16 0.956 
 
 20E and its dioxolane derivatives (with the exception of compounds 37-42) were tested 
in a combination assay with doxorubicin on L5178MDR cells, and all the derivatives showed 
synergistic activity, increasing the sensitivity of multi-drug resistant mouse lymphoma cells 
towards doxorubicin. This sensitizing effect was more pronounced in case of 2,3;20,22-
disubstituted dioxolanes compared to that of 20,22-monosubstituted ones. Based on the 
comparison of the C-28 and C-29 epimer pairs, it was found that at C-28, the larger 
substituent needs to take the R
2
-position while at C-29 the R
3
-position for a stronger 
activity. Increasing the length of the substituent coupled to C-29 led to a significant 
increase in activity till the length of three carbon atoms, however, a longer alkyl 
substituent appeared to be less preferable. Introducing larger aromatic groups did not lead 
to stronger activities, although further substituents on the aromatic ring were able to 
increase activity. Addition of a β-methyl group to C-29 could significantly increase the 
activity as compared to that of the 29α-phenyl substituted derivatives (see Table 4). 
 
Table 4 – Combination index (CI) values at 50%, 75% and 90% of inhibition at the most active constant 
ratio of compounds 1, 6-36 and 65-68, combined with doxorubicin on the ABCB1 transfected L5178MDR 
cell line. 0 < CI <1, CI = 1, CI > 1 represent synergism, additivity and antagonism, respectively. CIavg = 
(CI50 + 2 x CI75 + 3 x CI90)/6, r represents the linear correlation coefficient of the median-effect plot. 
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 Compounds 37-42 and 56-64 did not show considerable anti-proliferative activity on 
their own, therefore combination indices (CIs) were not calculated for them. However, 
they were still tested in combination with doxorubicin. These compounds exerted 
significant effect in the bioassay, which was even more pronounced in case of the side-
chain cleaved poststerone derivatives. Generally, with larger substituents connected to C-
2,3, higher activity was observed, which appeared to be most significant in case of an iso-
butyl group (see Table 5, results for compounds 37-42 are incomplete and are not listed). 
 
Table 5 – Chemo-sensitizing activity of poststerone (51) and its derivatives (56-64) on L5178 and 
L5178MDR cell lines. Values are presented as the average of 3 independent experiments ± standard 
error of the mean (SEM). With the exception of 10 μM of compound 51 (either cell line), and 56, 57 
and 63 (L5178), all IC50 values differ from that found for doxorubicin alone at p < 0.01 by means of one-
way ANOVA followed by Dunnett’s post-hoc test. 
 
compound 
IC50 (μM) of doxorubicin 
L5178 L5178MDR 
10 μM  25 μM 10 μM 25 μM 
control 0.41 ± 0.02 0.41 ± 0.02 11.83 ± 0.64 11.83 ± 0.64 
51 0.37 ± 0.01 0.29 ± 0.01 13.22 ± 0.44 7.55 ± 0.56 
56 0.34 ± 0.02 0.23 ± 0.01 3.80 ± 0.10 1.77 ± 0.08 
57 0.33 ± 0.01 0.15 ± 0.004 2.74 ± 0.66 1.39 ± 0.06 
58 0.26 ± 0.02 0.17 ± 0.007 1.74 ± 0.11 0.87 ± 0.08 
59 0.28 ± 0.02 0.20 ± 0.01 6.81 ± 0.33 3.00 ± 0.09 
60 0.21 ± 0.002 0.15 ± 0.01 1.56 ± 0.08 0.79 ± 0.05 
61 0.18 ± 0.003 0.12 ± 0.002 0.43 ± 0.02 0.17 ± 0.005 
62 0.19 ± 0.01 0.11 ± 0.003 2.60 ± 0.11 1.40 ± 0.08 
63 0.34 ± 0.02 0.26 ± 0.04 2.23 ± 0.14 1.47 ± 0.08 
64 0.24 ± 0.02 0.23 ± 0.02 1.59 ± 0.02 0.97 ± 0.03 
 
 Considering that some 20,22-monosubstituted dioxolane derivatives of 20E (namely 
compounds 7, 9, 12 and 18), and particularly most derivatives of poststerone (compounds 
57-60 and 62-64) sensitized the multi-drug resistant mouse lymphoma cells towards 
doxorubicin, but had very low FAR values, these compounds should exert their effect in a 
way other than a functional inhibition of the ABCB1 efflux pump. This makes these 
compounds particularly valuable, considering the several decades-long unsuccessful efforts 
for developing a clinically applicable inhibitor, there is a great need for new approaches 
against MDR. The observed structure-activity relationships are shown on Figure 6. 
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Figure 6 – SAR summary for ecdysteroid dioxolanes (6-42 and 56-68). Font types represent: normal – 
effect on anti-proliferative activity, italic – effect on ABCB1-inhibiting activity, bold – effect on chemo-
sensitizing activity to doxorubicin. “Greater than” symbols denote stronger synergistic activities, ↑ 
refers to increase in activity, and ᴓ means no effect. 
 
 Compounds 1, 6 and 20 were tested on other, human derived cell lines (two breast 
cancer and two prostate cancer cell lines) beside the mouse lymphoma cells, in 
combination with other chemotherapeutics (paclitaxel, cisplatin) than doxorubicin. 
Compound 20 could effectively sensitize non-MDR human cell lines with no detectable 
(MCF7) or very low (LNCaP) expression of the ABCB1 transporter, which supports our 
assumption that less polar ecdysteroids do not exclusively act as ABCB1 inhibitors. 
Compound 6 showed less potent activity than 20, and in most cases, the activity of 
compound 1 was considered to be irrelevant. Interestingly, however, all three compounds 
decreased the sensitivity of the cells towards cisplatin (see Table 6). 
 Some dioxolane derivatives (20, 31, 33, 34, 36) – identified as potentially being able to 
penetrate the blood-brain barrier – were also tested on the SH-SY5Y neuroblastoma cell 
line towards vincristine. All the tested compounds showed dose-dependent sensitizing 
activity, and compound 31 proved to be most potent: when applying at 10 μM, it 
decreased the IC50 value of vincristine by three orders of magnitude, to as low as 0.056 ± 
0.03 nM. This dramatic increase in the observed cytotoxic activity suggests the high 
sensitivity of this neuroblastoma cell line towards such combinational treatment. 
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 The oxidized ecdysteroid derivatives (43-50, with the exception of 45 and 49) were 
tested for their capacity to influence the Akt-phosphorylation in C2C12 myotubes. 
Compounds 44 and 47 significantly increased Akt-phosphorylation, while compound 48 – 
the desmotropic pair of 47 – showed the opposite effect at the applied concentration. This 
puzzling difference between the bioactivities of these isomers is of particular interest for 
further studies (see Figure 7). 
 
Figure 7 – Activity of compounds 43-44, 46-48 and 50 on the Akt-phosphorylation in murine skeletal 
muscle cells. Quantification of Western blots was performed by ImageJ; error bars represent SEM; **: 
p < 0.01; ***: p < 0.001 by one-way ANOVA followed by Bonferroni’s post hoc test; *: p < 0.05 by one-
way ANOVA performed in a planned comparison of 47 and 48 to the control (C) by using Dunnett’s 
post hoc test; n = 2-5. 
 
SUMMARY 
 63 ecdysteroid derivatives have been synthesized from 20E or other natural 
ecdysteroids, including 46 new compounds. These compounds were obtained by 
dioxolane formation, base-catalyzed autoxidation, side-chain cleavage or fluorination. 
 Most of the dioxolane compounds, including the 2,3-monosubstituted derivatives of 
20E (37-42) and those of poststerone (56-60 and 62-64) showed very weak or no anti-
proliferative activity on cancer cell lines. 
 Compounds 6-36 and 56-68 were tested for their ability to inhibit the ABCB1 
transporter: while some compounds showed marked inhibiton, most of them were 
weak in this regard; others (56-60 and 62-64) proved to be completely inactive. 
 Ecdysteroid dioxolanes (6-42 and 56-64) were found to act synergistically with 
doxorubicin on mouse T-cell lymphoma cells and particularly on the MDR cell line, with 
more pronounced activity in case of disubstituted dioxolanes and poststerone 
derivatives. Selected compounds showed synergistic activity on other cell lines as well, 
in combination with paclitaxel or vincristine, but exerted antagonistic effect with 
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cisplatin. SH-SY5Y neuroblastoma cells proved to be most sensitive towards the chemo-
sensitizing activity of ecdysteroid dioxolanes when combined with vincristine. 
 Our SAR studies on ecdysteroid dioxolanes revealed that they can be engineered to 
become inactive as functional ABCB1 inhibitors, while retaining a strong chemo-
sensitizing activity with a strong selectivity towards the ABCB1-transfected cancer cells.  
 Oxidized ecdysteroid derivatives (43-50) were tested for their activity on the Akt-
phosphorylation in C2C12 myotubes, and the difference observed between the 
bioactivities of a desmotropic pair (47 and 48) is of particular interest. To our best 
knowledge, our work represents the first report of such a phenomenon. 
 Further SARs were discovered concerning the anti-proliferative, ABCB1-inhibiting and 
chemo-sensitizing activity of ecdysteroid dioxolanes (6-42 and 56-68). In general, 
dioxolane formation and side-chain cleavage increases chemo-sensitizing activity. 
 Based on these findings, poststerone dioxolanes (56-64) can be highlighted as the most 
prospective leads for further research. 
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